<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2182-2395</journal-id>
<journal-title><![CDATA[Revista da Sociedade Portuguesa de Dermatologia e Venereologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Soc Port Dermatol Venereol]]></abbrev-journal-title>
<issn>2182-2395</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Dermatologia e Venereologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2182-23952021000200055</article-id>
<article-id pub-id-type="doi">10.29021/spdv.79.2.1305</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Isolated Limb Perfusion for the Treatment of Unresectable In-Transit Metastases of Cutaneous Squamous Cell Carcinoma]]></article-title>
<article-title xml:lang="pt"><![CDATA[Perfusão Isolada de Membro no Tratamento de Metástases em Trânsito de Carcinoma Espinocelular]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vieira]]></surname>
<given-names><![CDATA[Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Farricha]]></surname>
<given-names><![CDATA[Victor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalar Universitário de Lisboa Central Hospital de Santo António dos Capuchos Dermatology and Venereology Department]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Hospitalar Universitário de Coimbra Dermatology and Venereology Department ]]></institution>
<addr-line><![CDATA[Coimbra ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Português de Oncologia de Lisboa General Surgery Department ]]></institution>
<addr-line><![CDATA[Lisbon ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>06</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>06</month>
<year>2021</year>
</pub-date>
<volume>79</volume>
<numero>2</numero>
<fpage>55</fpage>
<lpage>57</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2182-23952021000200055&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2182-23952021000200055&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2182-23952021000200055&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Squamous cell carcinoma (SCC) is the second most common non-melanoma skin cancer and its incidence has been increasing over the past decades. SCC in-transit metastases are rare and predict a poor prognosis. We present the case of a 69-year-old patient with a right lower leg SCC, surgically excised with free margins. One month later, erythematous to violaceous, firm papules begin to erupt on the right lower leg, evolving to ulcerated nodules over a period of weeks. Homolateral inguinal and iliac nodal metastases were documented by percutaneous biopsy of an inguinal palpable lymph node and later documented by positron emission tomography - computed tomography (PET-CT). Given the unresectability of the disease, regional chemotherapy involving isolated limb perfusion (ILP) with melphalan and tumor necrosis factor-alpha (TNF&#945;) was performed in order to avoid amputation. Macroscopic regression ensued, with complete resolution of all visible in-transit metastases 12 weeks after perfusion. However, a fatal outcome was observed 4 months later, due to systemic metastases. ILP is an effective and well-established technique in the treatment of advanced tumors of the extremities. Its main indications are in-transit metastases of malignant melanoma and advanced soft tissue sarcomas. However, studies have shown its effectiveness in other tumors such as locally advanced SCC. Despite the unfortunate outcome, it was possible to avoid amputation of the limb, with complete local disease remission.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  O carcinoma espinocelular (CEC) é o segundo cancro cutâneo não-melanoma mais comum e a sua incidência tem aumentado nas últimas décadas. A metastização locoregional é rara e, quando ocorre, associa-se a um pior prognóstico. Apresenta-se o caso de uma doente de 69 anos, com CEC da perna direita, invasivo, moderadamente diferenciado, totalmente excisado cirurgicamente. Após 1 mês, a doente refere o aparecimento de pápulas eritematovioláceas, de consistência dura, que evoluíram para nódulos de 3-4 cm, ulcerados, localizados na perna direita. A invasão ganglionar inguinal e ilíaca homolateral foi documentada através de punção aspirativa de conglomerado adenopático palpável a esse nível e posteriormente documentado por tomografia de emissão de positrões com TC (PET-TC). Dada a irressecabilidade cirúrgica da doença, foi realizada uma perfusão isolada de membro (PIM) com melfalan e fator de necrose tumoral (TNF&#945;) para evitar a amputação. Foi observada resolução completa de todas as metástases em trânsito 12 semanas após a perfusão. No entanto, 4 meses depois, a progressão sistémica da doença culminou num desfecho fatal. A PIM é uma técnica eficaz e bem estabelecida no tratamento de tumores avançados das extremidades. As suas principais indicações são as metástases em trânsito de melanoma maligno e sarcomas de partes moles. No entanto, estudos demonstram a sua eficácia no tratamento de outros tumores, como é o caso do CEC localmente avançado. Apesar de não ter alterado o prognóstico da doença, foi possível, com a abordagem instituída, evitar a amputação do membro, atingindo a remissão completa da doença localizada.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Amputation]]></kwd>
<kwd lng="en"><![CDATA[Carcinoma, Squamous Cell]]></kwd>
<kwd lng="en"><![CDATA[Extremities]]></kwd>
<kwd lng="en"><![CDATA[Neoplasm Metastasis]]></kwd>
<kwd lng="pt"><![CDATA[Amputação]]></kwd>
<kwd lng="pt"><![CDATA[Carcinoma de Células Escamosas]]></kwd>
<kwd lng="pt"><![CDATA[Extremidades]]></kwd>
<kwd lng="pt"><![CDATA[Metástase Neoplásica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samarasinghe]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Madan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nonmelanoma Skin Cancer]]></article-title>
<source><![CDATA[J Cutan Aesthet Surg]]></source>
<year>2012</year>
<volume>5</volume>
<page-range>3-10</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez Herevia]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Isolated limb perfusion on nonmelanoma skin cancer for limb salvage a series of four cases]]></article-title>
<collab>Tavares de la Paz LA.Hinojosa Ugarte D.Nieves Condoy J</collab>
<source><![CDATA[Cureus]]></source>
<year>2020</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alegre]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sureda González]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bretcha Boix]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dussan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ballester]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento regional del sarcoma y melanoma localmente avanzado de la extremidad mediante la perfusión aislada con tumor necrosis factor a y melfalan asociada a hipertermia]]></article-title>
<source><![CDATA[Cir Esp]]></source>
<year>2012</year>
<volume>90</volume>
<page-range>114-20</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>Huis In 't Veld EA.Grünhagen DJ.Deroose JP.Nijsten TC.Wouters MW.Verhoef C</collab>
<article-title xml:lang=""><![CDATA[Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>2018</year>
<volume>119</volume>
<page-range>429-34</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Creech]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Krementz]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Winblad]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemotherapy of cancer regional perfusion utilizing an extracorporeal circuit]]></article-title>
<source><![CDATA[Ann Surg]]></source>
<year>1958</year>
<volume>148</volume>
<page-range>616-32</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhangu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Broom]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nepogodiev]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gourevitch]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma a systematic review]]></article-title>
<source><![CDATA[Eur J Surg Oncol]]></source>
<year>2013</year>
<volume>39</volume>
<page-range>311-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belgrano]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ben-Shabat]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bergh]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bagge]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Isolated limb perfusion as a treatment option for rare types of tumours]]></article-title>
<source><![CDATA[Int J Hyperthermia]]></source>
<year>2016</year>
<volume>32</volume>
<page-range>595-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Combalia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carrera]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Squamous cell carcinoma an update on diagnosis and treatment]]></article-title>
<source><![CDATA[Dermatol Pract Concept]]></source>
<year>2020</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brantsch]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Meisner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schönfisch]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Trilling]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wehner-Caroli]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Röcken]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma a prospective study]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2008</year>
<volume>9</volume>
<page-range>713-20</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[JZ]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Special concern about squamous cell carcinoma of the scalp in organ transplant recipients]]></article-title>
<source><![CDATA[Arch Dermatol]]></source>
<year>2006</year>
<volume>142</volume>
<page-range>755-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponte]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moniz]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Farricha]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Weinholtz]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Merkel cell carcinoma an unusual indication for isolated limb perfusion]]></article-title>
<source><![CDATA[Dermatol Online J]]></source>
<year>2008</year>
<volume>14</volume>
<page-range>6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olieman]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Liénard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Eggermont]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Kroon]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Lejeune]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hoekstra]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities a multicenter study]]></article-title>
<source><![CDATA[Arch Surg]]></source>
<year>1999</year>
<volume>134</volume>
<page-range>303-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aloia]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Grubbs]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Onaitis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mosca]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[TY]]></given-names>
</name>
<name>
<surname><![CDATA[Seigler]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response]]></article-title>
<source><![CDATA[Arch Surg.]]></source>
<year>2005</year>
<volume>140</volume>
<page-range>1115-20</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koops]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Vaglini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Suciu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kroon]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Göhl]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1998</year>
<volume>16</volume>
<page-range>2906-12</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
